HiTech Pharmacal Co News

HiTech Pharmacal Co. Inc. filed Quarterly Report for the period ended 2009-10-31. Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing branded and generic products.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Hi-Tech Pharmacal Co. said Wednesday its fiscal second-quarter profit surged due to strong sales of generic drugs.

Net income: Profit of $7.4 million, compared with a profit of $1.1 million in the same period last year.

Posted 08:00 AM ET AMITYVILLE, N.Y., Dec 04, 2009 -- Hi-Tech Pharmacal Co., Inc.

Hi-Tech Pharmacal Co . obtained the approval Nov. 19 from the Food and Drug Administration .

Amityville-based pharmaceutical company Hi-Tech Pharmacal on Monday said it has signed a deal to market Zolpimist, a drug used to treat insomnia, in the United States and Canada.

The NASDAQ OMX Group, Inc. announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index , which will become effective with the market open on Monday, November 23, 2009.

The trust pari... NEW YORK-- --Fitch Ratings has downgraded, revised Loss Severity ratings and maintained a Negative Outlook on 19 classes from three U.S. CMBS transactions due to increased loss expe... LAS VEGAS-- --NV Energy, Inc.

CEO, President, Sec'y, Treas., 10% Owner of HiTech Pharmacal Co. Inc. David S Seltzer sells 40,000 shares of HITK on 09/29/2009 at an average price of $21.49 a share.

Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value.

Hi Tech Pharmacal issued better-than-expected Q2 results. ISTA gets FDA approval for Bepreve in allergic conjunctivitis; separate T-Pred study may weigh on shares.

Stocks pared some gains following the Fed's beige book report, but they bounced back in the final hour.

After a surge in last weeka s mortgage applications and led by surging industrial stocks, the major indices were all in the green with the Dow up 0.5%, to 9547.22, the S&P 500 gaining 0.8% and the Nasdaq up 1.11%. Here are some of Wednesdaya s winners and losers: Winners Vivus Inc.

The Talbots, Inc second quarter revenues fell 23% to $304.6 million and net loss was $24.5 million or 45 cents a share.

Hi-Tech Pharmacal Co. said Wednesday its fiscal first-quarter profit climbed more than fivefold due to strong sales of new generic drugs, including treatments for ear infections.

Delmar, CA - FaceBook is a phenomenal social marketing tool in today's world. Successful stock investors are finding FaceBook to be extremely helpful in following the winning stock picks that are making the money on the stock market while cutting out unnecessary articles at the same time that they are searching for these stock picks.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Noven Pharmaceuticals announced it agreed to be acquired by Japan's Hisamitsu Pharmaceutical, for $16.50 per share in cash, a deal valued at $428 million.

LiquidTycoon.com is pleased to alert investors of stocks on the move. Hi-Tech Pharmacal Co surged up on high volumes.